• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,794.60
  • -0.61 %
  • -$257.59
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,204.52
  • 0.25 %
  • $20.28
  • IXIC
  • $18,179.98
  • -0.33 %
  • -$59.93
Mirati Therapeutics, Inc. (MRTX) Stock Price, News & Analysis

Mirati Therapeutics, Inc. (MRTX) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$58.54
Day's range
$58.99
50-day range
$55.61
Day's range
$59.46
  • Country: US
  • ISIN: US60468T1051
52 wk range
$27.3
Day's range
$64.41
  • CEO: Dr. Charles M. Baum M.D., Ph.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 8.54
  • Piotroski Score 4.00
  • Grade Neutral
  • Symbol (MRTX)
  • Company Mirati Therapeutics, Inc.
  • Price $58.70
  • Changes Percentage (-0.17%)
  • Change -$0.1
  • Day Low $58.54
  • Day High $58.99
  • Year High $64.41

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $66.50
  • High Stock Price Target $247.00
  • Low Stock Price Target $53.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$12.18
  • Trailing P/E Ratio -4.8193760262726
  • Forward P/E Ratio -4.8193760262726
  • P/E Growth -4.8193760262726
  • Net Income $-740,867,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.